RTI Biologics, Inc. (RTIX) Tops Q3 EPS by 2c, Raises FY11 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts RTIX Hot Sheet
Price: $3.14 --0%
Financial Fact:
Total operating expenses: 37.6M
Today's EPS Names:
OMID, SICP, SCKT, More
Financial Fact:
Total operating expenses: 37.6M
Today's EPS Names:
OMID, SICP, SCKT, More
Join SI Premium – FREE
RTI Biologics, Inc. (NASDAQ: RTIX) reported Q3 EPS of $0.05, $0.02 better than the analyst estimate of $0.03. Revenue for the quarter came in at $42.3 million versus the consensus estimate of $40.44 million.
RTI Biologics, Inc. sees FY2011 EPS of $0.12-$0.14, versus the consensus of $0.13. RTI Biologics, Inc. sees FY2011 revenue of $164-$166 million, versus the consensus of $165.94 million.
RTI Biologics, Inc. sees FY2011 EPS of $0.12-$0.14, versus the consensus of $0.13. RTI Biologics, Inc. sees FY2011 revenue of $164-$166 million, versus the consensus of $165.94 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teradyne (TER) Tops Q3 EPS by 21c, Beats on Revenue; Offers Q4 EPS Guidance
- NXP Semiconductors (NXPI) Tops Q3 EPS by 9c
- RenaissanceRe (RNR) Tops Q3 EPS by 241c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
